IL106516A - Triacolithiomilato splosporin hydrochloride, its crystalline hydrate and the above production and a pharmaceutical mixture containing - Google Patents

Triacolithiomilato splosporin hydrochloride, its crystalline hydrate and the above production and a pharmaceutical mixture containing

Info

Publication number
IL106516A
IL106516A IL106516A IL10651693A IL106516A IL 106516 A IL106516 A IL 106516A IL 106516 A IL106516 A IL 106516A IL 10651693 A IL10651693 A IL 10651693A IL 106516 A IL106516 A IL 106516A
Authority
IL
Israel
Prior art keywords
hydrochloride
crystalline hydrate
crystalline
hydrate
water
Prior art date
Application number
IL106516A
Other languages
English (en)
Hebrew (he)
Other versions
IL106516A0 (en
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of IL106516A0 publication Critical patent/IL106516A0/xx
Publication of IL106516A publication Critical patent/IL106516A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D501/00Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL106516A 1992-07-31 1993-07-28 Triacolithiomilato splosporin hydrochloride, its crystalline hydrate and the above production and a pharmaceutical mixture containing IL106516A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP20496592 1992-07-31

Publications (2)

Publication Number Publication Date
IL106516A0 IL106516A0 (en) 1993-11-15
IL106516A true IL106516A (en) 1998-06-15

Family

ID=16499234

Family Applications (1)

Application Number Title Priority Date Filing Date
IL106516A IL106516A (en) 1992-07-31 1993-07-28 Triacolithiomilato splosporin hydrochloride, its crystalline hydrate and the above production and a pharmaceutical mixture containing

Country Status (23)

Country Link
US (1) US5407929A (el)
EP (1) EP0581552B1 (el)
KR (1) KR100245938B1 (el)
CN (1) CN1037683C (el)
AT (1) ATE165360T1 (el)
AU (1) AU657866B2 (el)
BR (1) BR9303235A (el)
CA (1) CA2101502A1 (el)
DE (1) DE69318077T2 (el)
ES (1) ES2115725T3 (el)
FI (1) FI933391A (el)
GR (1) GR3026699T3 (el)
HU (1) HU219637B (el)
IL (1) IL106516A (el)
MX (1) MX9304611A (el)
NO (1) NO303734B1 (el)
NZ (1) NZ248285A (el)
PH (1) PH30109A (el)
PL (2) PL172835B1 (el)
RU (1) RU2118959C1 (el)
TW (1) TW307769B (el)
UA (1) UA37181C2 (el)
ZA (1) ZA935529B (el)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2444772T3 (es) * 2001-02-24 2014-02-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Derivados de xantina, su preparación y uso como medicamentos
AT413282B (de) * 2002-02-01 2006-01-15 Sandoz Ag Kristalline salze der 7-(((5-amino-1,2,4-thiadiazol-3-yl) (fluoromethoxy-imino)acetyl)amino)-3- ((imino-1-piperazinylmethyl)
KR20030076759A (ko) * 2002-03-21 2003-09-29 주식회사 엘지생명과학 신규 세팔로스포린 화합물 및 그의 제조 방법
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US6727277B1 (en) 2002-11-12 2004-04-27 Kansas State University Research Foundation Compounds affecting cholesterol absorption
DE202004021379U1 (de) 2003-02-12 2008-02-21 Ciba Specialty Chemicals Holding Inc. Kristalline Formen von Pitivastatin Calcium
AU2004224181B2 (en) 2003-03-27 2011-06-02 Basilea Pharmaceutica Ag Cephalosporin in crystalline form
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
UA97244C2 (en) 2006-05-04 2012-01-25 Берингер Ингельхайм Интернациональ Гмбх Polymorphs of 1-((4-methyfquinazolin-2-yl)methyl)-3-methyl-7- (2-butyn-1-yl)-8-(3-(r)-aminopiperidin-l-yl)xanthine
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
ES2733348T3 (es) * 2007-08-17 2019-11-28 Boehringer Ingelheim Int Derivados de purina para uso en el tratamiento de enfermedades relacionadas con FAP
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR101657960B1 (ko) * 2008-08-15 2016-09-20 베링거 인겔하임 인터내셔날 게엠베하 Fab-관련 질환의 치료에 사용하기 위한 푸린 유도체
AU2009290911A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN102256976A (zh) 2008-12-23 2011-11-23 贝林格尔.英格海姆国际有限公司 有机化合物的盐形式
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
KR20190071840A (ko) 2009-11-27 2019-06-24 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 dpp-iv 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
ES2935300T3 (es) 2010-05-05 2023-03-03 Boehringer Ingelheim Int Combiterapia
CN106975074A (zh) 2010-06-24 2017-07-25 勃林格殷格翰国际有限公司 糖尿病治疗
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
US8883800B2 (en) 2011-07-15 2014-11-11 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Dpp−4阻害薬の医学的使用
EP3468562A1 (en) 2016-06-10 2019-04-17 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE65926B1 (en) * 1990-07-19 1995-11-29 Shionogi & Co Thioalkylthio cephalosporin derivatives

Also Published As

Publication number Publication date
UA37181C2 (uk) 2001-05-15
NO303734B1 (no) 1998-08-24
EP0581552B1 (en) 1998-04-22
PL172830B1 (pl) 1997-12-31
NZ248285A (en) 1994-07-26
AU4422793A (en) 1994-02-03
US5407929A (en) 1995-04-18
ZA935529B (en) 1994-02-24
HU219637B (hu) 2001-06-28
DE69318077D1 (de) 1998-05-28
DE69318077T2 (de) 1998-10-29
AU657866B2 (en) 1995-03-23
KR940005636A (ko) 1994-03-22
KR100245938B1 (ko) 2000-04-01
FI933391A0 (fi) 1993-07-29
IL106516A0 (en) 1993-11-15
PL299870A1 (en) 1994-02-07
GR3026699T3 (en) 1998-07-31
HUT68602A (en) 1995-06-28
ES2115725T3 (es) 1998-07-01
FI933391A (fi) 1994-02-01
ATE165360T1 (de) 1998-05-15
HU9302194D0 (en) 1993-10-28
EP0581552A3 (en) 1994-06-01
EP0581552A2 (en) 1994-02-02
PH30109A (en) 1996-12-27
CA2101502A1 (en) 1994-02-01
TW307769B (el) 1997-06-11
MX9304611A (es) 1994-02-28
BR9303235A (pt) 1994-03-01
CN1089948A (zh) 1994-07-27
CN1037683C (zh) 1998-03-11
NO932745L (no) 1994-02-01
PL172835B1 (pl) 1997-12-31
RU2118959C1 (ru) 1998-09-20
NO932745D0 (no) 1993-07-30

Similar Documents

Publication Publication Date Title
EP0581552B1 (en) Triazolylthiomethylthio cephalosporin hyrochloride, its crystalline hydrate and the production of the same
US20060149056A1 (en) Stable bioavailable crystalline form of cefdinir and a process for the preparation thereof
JPH0128036B2 (el)
FI72978C (fi) Foerfarande foer franstaellning av som laekemedel anvaendbara alkyl-(eller alkoxi-)-karbonyloxialkyl-7-/2-(2- aminotiazol-4-yl)-2-hydroxiiminoacetamido/-3-metoximetyl-3-cefem-4- karboxylat.
JPH0245634B2 (el)
CA2002596A1 (en) Hydrates of b-lactam antibiotic
JPS63107989A (ja) セファロスポリン化合物
AU2006300882B2 (en) Crystalline sodium salt of cephalosporin antibiotic
US4189479A (en) Cephalosporin esters
EP0547646B1 (en) Crystalline form of a cephalosporin antibiotic
KR0158883B1 (ko) 결정성 세펨산 부가염 및 이의 제조방법
JPH0741484A (ja) セフェム化合物及び抗菌剤
JPS6232194B2 (el)
JP2575590B2 (ja) トリアゾリルチオメチルチオセファロスポリン塩酸塩およびその水和物結晶ならびにそれらの製法
IE910251A1 (en) Crystalline hydrochloride of new beta-lactam antibiotic and¹process therefor
WO2010020871A2 (en) Crystalline sodium salt of cephalosporin antibiotic
IE47929B1 (en) Substituted imidazolidinyl-3-chloro-3-cephem-4-carboxylic acids
US4497811A (en) 1-Oxadethiacephalosporin compound and antibacterial agent containing the _same
GB2091263A (en) 7-((carboxy-methoximino)-lh-pyrazol-3-yl-acetyl))-amino-3-desacetoxy-3-(l-methyl-lh-tetrazol-5-yl-thio)cepha 10-sporanic acid
US4405618A (en) Thiazolidine derivatives with antibiotic activity
EP0098615B1 (en) 1-oxadethiacephalosporin compound and antibacterial agent containing the same
NO884417L (no) Monohydrat og solvater av et nytt beta-laktam-antibiotikumog fremgangsmaate for fremstilling derav.
DE3346775A1 (de) Oxacephalosporine und verfahren zu ihrer herstellung
SI8510745A8 (sl) Postopek za pripravo soli-hidratov derivatov cefalosporina
WO1988010263A1 (en) Crystalline cephalosporin compounds, process for their preparation, and intermediates for their preparation

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
RH1 Patent not in force